Clinical trial

COMMETS- Combination MCI Metabolic Syndrome

NCT06072963

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-01-30

PhasePHASE2

Study timeline

Study start (actual)2024-01-30Date precision: day

Registry last updated2026-07-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alzheimer Diseaseunresolved

Mild Cognitive Impairmentunresolved

Metabolic Syndromeunresolved

Interventions

SemaglutideDRUG · verified · RxNorm: semaglutide

Intranasal insulinDRUG

Semaglutide placeboOTHER

Intranasal insulin placeboOTHER

Sponsors & collaborators

Rutgers, The State University of New Jerseylead sponsor

Alzheimer's Associationcollaborator

Mapped research locations

Ramat GanIsrael1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06072963 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.